翰森製藥(03692.HK)晚期乳腺癌治療藥物獲臨牀試驗通知書
格隆匯5月18日丨翰森製藥(03692.HK)宣佈,由公司附屬公司江蘇豪森藥業集團有限公司及上海翰森生物醫藥科技有限公司自主研發的1類新藥"HS-10352片"於2020年5月18日獲得中華人民共和國國家藥品監督管理局核准簽發的臨牀試驗通知書,擬用於治療磷脂醯肌醇3激酶α型突變陽性(PIK3CA+)激素受體陽性(HR+)人表皮生長因子受體2陰性(HER2-)的晚期乳腺癌。最終適應症待臨牀研究後確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.